Mayne Pharma Launches US Pharmacy Platform to Cut Middlemen and Capture Margins

Mayne Pharma launches DistributeRx to reshape US prescription fulfilment

Mayne Pharma Group Limited (ASX: MYX) has announced the Mayne Pharma DistributeRx Launch on 10 March 2026, establishing a healthcare solutions business designed to streamline prescription distribution and expand patient access in the US market. The initiative creates a direct-to-patient sales channel through Adelaide Apothecary, offering transparent cash-pay pricing when patients face insurance coverage challenges, thereby improving pricing control and reducing reliance on traditional intermediaries.

DistributeRx operates as a wholly owned subsidiary of Mayne Pharma, aligning with the company’s broader disintermediation strategy to expand patient access and improve product gross margins. Management has positioned the launch as a strategic milestone targeting Women’s Health and Dermatology sectors, with the business structured to support branded, authorised generic, generic, specialty and non-specialty medications through its licensed pharmacy partner, CoAssist Pharmacy.

How DistributeRx works

The DistributeRx ecosystem integrates three operational arms to connect prescription generation with patient fulfilment:

1. Customer-facing services: Utilises existing GoodRx-enabled prescribing access and Adelaide Apothecary cash-pay capability to provide patients with transparent pricing options and home delivery.
2. Manufacturer services: Offers co-pay programme optimisation, enhanced fulfilment solutions, and direct-to-pharmacy contracting to third-party manufacturers, leveraging Mayne Pharma’s distribution and access expertise.
3. Pharmacy services: Powered by CoAssist Pharmacy, a licensed pharmacy providing compliant fulfilment pathways for multiple medication categories.

The architecture functions as an integrated digital “front door” that connects prescriber workflow and patient onboarding with benefit checks and intelligent fulfilment routing. When insurance coverage is available, patients are triaged appropriately. Where coverage challenges exist, Adelaide Apothecary provides cash-pay fulfilment through its direct-to-patient programmes.

The system is designed to capture and accelerate US direct-to-patient behaviour, improve prescription fulfilment speed, and strengthen data visibility and unit economics across Mayne Pharma’s portfolio. DistributeRx operates the channel, whilst CoAssist Pharmacy manages the compliant fulfilment pathway, creating a scalable foundation capable of supporting multiple medication types and specialty areas.

For investors, the integrated ecosystem positions Mayne Pharma to capture direct-to-patient market share whilst improving revenue quality through reduced intermediary dependence. The manufacturer services arm creates an additional revenue stream without significant capital investment, as the company monetises its existing distribution knowledge and infrastructure across the broader pharmaceutical industry.

What is disintermediation in pharma?

Disintermediation refers to the removal of intermediaries (such as wholesalers and pharmacy benefit managers) from the pharmaceutical supply chain, allowing manufacturers to connect more directly with patients. Traditional supply chains involve multiple mark-ups at each distribution stage, reducing manufacturer control over final pricing and eroding gross margins through intermediary fees.

By shortening the supply chain, manufacturers gain improved pricing transparency, enhanced data visibility into patient behaviour, and greater control over the patient experience. This structural change supports margin expansion by eliminating intermediary mark-ups whilst providing manufacturers with direct access to prescribers and patients.

For Mayne Pharma, DistributeRx represents the operational execution of this disintermediation strategy. Rather than relying solely on traditional distribution channels, the company has built proprietary infrastructure to fulfil prescriptions directly, capturing margin that would otherwise flow to intermediaries. The manufacturer services component extends this benefit to third-party pharmaceutical companies, creating a scalable revenue opportunity with limited capital requirements.

Investors should recognise disintermediation as a structural improvement in revenue quality rather than a purely cost-cutting initiative. The approach supports margin sustainability by reducing exposure to intermediary pricing pressures whilst enhancing Mayne Pharma’s ability to serve patients directly across its Women’s Health and Dermatology focus areas.

Market opportunity and growth tailwinds

The direct-to-patient and virtual pharmacy fulfilment market continues to expand, supported by structural shifts in US healthcare delivery. Independent research firm Precedence Research has estimated the global ePharmacy market size and growth trajectory through 2030:

This growth is underpinned by rising consumer adoption of digital pharmacy services, home delivery preferences, accelerating direct-to-patient initiatives, and increased telehealth utilisation in relevant therapeutic categories. These trends aim to reduce friction in the prescription-to-fulfilment pathway, aligning with patient and prescriber expectations for convenient digital access, transparent pricing, and reliable delivery.

Mayne Pharma is positioning itself to capture a portion of this expanding market through DistributeRx’s integrated infrastructure. The company expects the healthcare solutions business to enhance engagement with prescribing clinicians, improve prescription access, and support stronger product economics over time as the US pharmacy ecosystem continues to evolve.

For investors, the market opportunity represents a scalable foundation for revenue growth beyond Mayne Pharma’s existing product portfolio. The 17% CAGR through 2030 provides structural tailwinds that support the commercial rationale for building direct-to-patient capability, particularly as traditional distribution channels face ongoing pricing pressure and margin compression.

Management commentary

Management has framed the Mayne Pharma DistributeRx Launch as addressing gaps in the current prescription fulfilment system:

Daniel Moore, President of DistributeRx

“DistributeRx was built to bridge the growing gap between patients and the therapies they need. By eliminating unnecessary complexity in the prescription process, we’re delivering a simple, transparent and affordable way for patients to access their medications. This is not just about convenience—it’s about restoring trust and control for manufacturers, prescribers and patients alike.”

Chief Executive Officer Aaron Gray positioned the launch within Mayne Pharma’s broader transformation objectives:

Aaron Gray, CEO of Mayne Pharma

“The launch of DistributeRx represents a major milestone in our transformation to a more focused and agile business. This solution enhances our ability to serve providers and patients directly, as well as other manufacturers, especially in Women’s Health and Dermatology. It will improve the quality of our revenues and unlock greater operating leverage across the portfolio.”

Management’s commentary explicitly links DistributeRx to revenue quality improvement and operating leverage, signalling expectations for margin expansion as the business scales. The emphasis on serving both Mayne Pharma’s portfolio and third-party manufacturers highlights the dual revenue model underpinning the initiative.

An investor webinar is scheduled for 11.00am AEDT on 11 March 2026 (8.00pm US Eastern Time on 10 March 2026), where CEO Aaron Gray, DistributeRx President Daniel Moore, and VP Sales & Marketing Meredith Gambill will provide additional detail on the digital fulfilment model and strategic rationale.

Investment thesis and outlook

The Mayne Pharma DistributeRx Launch represents a strategic shift toward higher-quality revenues and improved operating leverage, supporting the company’s margin expansion objectives. The initiative addresses multiple investment considerations:

• Direct-to-patient channel: Improves gross margin control by reducing intermediary dependence and capturing margin that would otherwise flow to wholesalers and pharmacy benefit managers.
• Manufacturer services revenue stream: Creates a new income source with limited capital investment, monetising Mayne Pharma’s distribution and access expertise across the broader pharmaceutical industry.
• Scalable infrastructure: The integrated digital architecture can support multiple specialties and medication types, providing a foundation for growth beyond the current portfolio.
• Structural alignment: Positioned to capture market share in the expanding ePharmacy sector, forecast to grow at 17% CAGR through 2030, driven by digital pharmacy adoption and direct-to-patient initiatives.
• Women’s Health and Dermatology focus: Aligns with Mayne Pharma’s stated commitment to strengthen its specialty portfolio, leveraging existing therapeutic expertise whilst building direct prescriber and patient relationships.

The non-capital-intensive nature of the manufacturer services offering enhances the investment case, as Mayne Pharma can generate incremental revenue without proportional capital deployment. Management’s focus on “quality of revenues” and “operating leverage” signals expectations for margin improvement as DistributeRx scales, rather than purely volume-driven growth.

For shareholders, the launch represents operational execution of the disintermediation strategy previously outlined by management. The combination of direct-to-patient capability through Adelaide Apothecary and third-party manufacturer services creates diversified revenue pathways, reducing concentration risk whilst supporting sustainable margin expansion across the portfolio.

Get Healthcare News Before the Market Reacts

Join 20,000+ investors receiving FREE breaking ASX healthcare alerts delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get market-moving pharmaceutical and biotech announcements in your inbox the moment they drop.